Viking Therapeutics is developing a weight loss medicine in the same general class as Eli Lilly's tirzepatide. The mid-cap biotech is exploring options for a potential quadruple agonist therapy.

Drug giant Eli Lilly is launching an AI-powered drug discovery platform. While it won't generate any revenue, this initiative could pay off in the long run. Still, there are plenty of other reasons to ...

Eli Lilly and Company’s LLY stock has risen 9.5% in a month, mainly due to the recent recovery in the pharma sector. The drug and biotech sector has recovered in the past month, with large drugmakers ...

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also ...